FindTrial
Sign In

UFT/LEUCOVORIN AND MITOMYCIN C IN THE TREATMENT OF METASTATIC COLORECTAL CANCER OXALIPLATIN AND IRINOTECAN RESISTANT - MITOUFT

UFT/LEUCOVORIN AND MITOMYCIN C IN THE TREATMENT OF METASTATIC COLORECTAL CANCER OXALIPLATIN AND IRINOTECAN RESISTANT - MITOUFT

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-006151-40-IT
Enrollment
Unknown
Registered
2007-11-28
Start date
2007-12-29
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PATIENTS WITH METASTATIC COLON-RECTAL CANCER MedDRA version: 9.1 Level: LLT Classification code 10052358 Term: Colorectal cancer metastatic

Interventions

Trade Name: UFT*42CPS Pharmaceutical Form: Capsule, hard INN or Proposed INN: TEGAFUR/URACILE CAS Number: 17902-23-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number

Sponsors

AZIENDA OSPEDALIERA S. LUIGI GONZAGA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: PATIENTS WITH DIAGNOSIS OF METASTATIC COLORECTAL CANCER OXALIPLATIN AND IRINOTECAN RESISTANT Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: PREVIOUS CHEMOTHERAPY WITH MITHOMYCIN C AND/OR UFT/LEUCOVORIN

Design outcomes

Primary

MeasureTime frame
Main Objective: ACTIVITY OF THE THERAPEUTICAL COMBINATIONS IN TERMS OF OBJECTIVE RESPONSES;Secondary Objective: 1 - TIME TO PREGRESSION 2- TOXICITY 3 - OVERALL SURVIVAL;Primary end point(s): OBJECTIVE RESPONSE—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026